RT @Sameh_VuMedi@twitter.com
Dr. Erika Hamilton @ErikaHamilton9@twitter.com @SarahCannonDocs@twitter.com discussing Dose-Expansion Study DESTINY-Breast07: T-DXd as Monotherapy or Combined With #Pertuzumab in pts With Metastatic #HER2+ #breastcancer from #SABCS22 #bcsm #mBC #VuMedi #OncTwitter #MedTwitter
🐦🔗: https://twitter.com/Sameh_VuMedi/status/1605960936535117828
#pertuzumab #her2 #breastcancer #SABCS22 #bcsm #MBC #vumedi #OncTwitter #medtwitter